Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

214/433 Matches for
“fatty liver”

“fatty liver” Clear all
  1. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 100

    …the SteatoTest; the fatty liver index (FLI); regular abdominal ultrasound (AUS); and…

    SteatoTest Metabolic

  2. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 100

    FibroTest SteatoTest Metabolic

  3. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 100

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  4. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 100

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  5. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 100

    Fatty liver was diagnosed with abdominal ultrasound and liver steatosis was quantified…

    FibroTest SteatoTest Metabolic

  6. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 99

    ### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…

    ActiTest FibroTest SteatoTest Metabolic

  7. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 99

    …4 (FIB-4), non-alcoholic fatty liver disease fibrosis score (NFS), body…

    FibroTest Metabolic

  8. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 99

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  9. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 99

    …of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is invasive…

    FibroTest Metabolic

  10. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.

    Sberna AL et al. · Diabet Med · 2018 Match 98

    Liver fat content (assessed using proton magnetic resonance spectroscopy), fatty liver index…

    FibroTest NashTest Metabolic

  11. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 98

    …Given that early identification of non-alcoholic fatty liver disease (NAFLD) is…

    NashTest SteatoTest Metabolic

  12. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 98

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  13. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 98

    …developing complications of end-stage liver disease. Although it lacks sensitivity, ultrasonography…

    ActiTest FibroTest NashTest SteatoTest +1

  14. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 97

    …CAP was significantly correlated with SteatoTest, Fatty Liver Index (FLI), percentage of…

    SteatoTest Metabolic

  15. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 97

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  16. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 97

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  17. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.

    Petroff D et al. · Dig Liver Dis · 2018 Match 97

    FibroTest Metabolic

  18. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 97

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  19. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 96

    …factors of liver disease, such as non-alcoholic fatty liver disease, hazardous…

    FibroTest Other

  20. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 96

    …potential contributing factor for nonalcoholic fatty liver disease (NAFLD). NAFLD severity and…

    FibroTest NashTest SteatoTest Metabolic

  21. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.

    Monneret D · F1000Res · 2017 Match 96

    The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…

    FibroTest NashTest SteatoTest Metabolic

  22. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 96

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver

    FibroTest NashTest SteatoTest HIV

  23. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 95

    ### Unlabelled Physical activity (PA) is commonly recommended for nonalchoholic fatty liver disease…

    SteatoTest Metabolic

  24. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 95

    …In multivariate analysis, the predictive variables for advanced liver fibrosis were age…

    FibroTest Metabolic

  25. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 95

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  26. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 95

    …of liver morbidity and mortality in non-alcoholic fatty liver disease (NAFLD…

    FibroTest Metabolic

  27. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 94

    …the limitations of similar European (Fatty Liver Inhibition of Progression) and USA…

    ActiTest FibroTest NashTest NashTest-2 +3

  28. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 94

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  29. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 94

    …risk factor for non-alcoholic fatty liver disease (NAFLD) occurrence and progression…

    NashTest SteatoTest Metabolic

  30. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 94

    …one hand and non-alcoholic fatty liver disease (NAFLD) on the other…

    ActiTest FibroTest NashTest SteatoTest +1

  31. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Match 93

    Liver biopsy is considered as the gold standard for assessing nonalcoholic fatty

    FibroTest NashTest SteatoTest Metabolic

  32. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 93

    ActiTest AshTest FibroTest NashTest +6

  33. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 93

    fatty liver disease with liver biopsy, blood fibrosis tests (Nonalcoholic Fatty Liver

    FibroTest Metabolic

  34. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 93

    FibroTest Metabolic

  35. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 93

    FibroTest Metabolic

  36. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 92

    …ELF, ≥10.43; Nonalcoholic Fatty Liver Disease Fibrosis Score, ≥1.80; Fibrotest…

    FibroTest Metabolic

  37. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 92

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  38. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 92

    …ActiTest, FIB4, BARD, and nonalcoholic fatty liver disease scores. A combination of…

    FibroTest NashTest SteatoTest Metabolic

  39. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 92

    ActiTest FibroTest NashTest-2 Metabolic

  40. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 91

    …standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions in…

    ActiTest FibroTest NashTest SteatoTest +1

  41. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013 Match 91

    FibroTest Metabolic

  42. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease.

    Ivancovsky-Wajcman D et al. · Dig Liver Dis · 2019 Match 91

    ### Background & Aims Although antioxidants have a protective potential in nonalcoholic fatty liver

    FibroTest NashTest SteatoTest Metabolic

  43. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 91

    …standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions. The…

    FibroTest Metabolic

  44. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 90

    …Beyond its utility in assessing liver fibrosis, the FibroTest® could be a…

    ActiTest FibroTest NashTest SteatoTest +1

  45. Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

    Chiou YL et al. · J Am Coll Nutr · 2021 Match 90

    ### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…

    ActiTest FibroTest SteatoTest Metabolic

  46. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 90

    ### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…

    NashTest-2 SteatoTest-2 Metabolic

  47. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 90

    …histologic lesions of non-alcoholic fatty liver disease (NAFLD). The aim was…

    NashTest Metabolic

  48. FibroMAX: towards a new universal biomarker of liver disease?

    Morra R et al. · Expert Rev Mol Diagn · 2007 Match 90

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest AshTest FibroTest NashTest +7

  49. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 89

    …CHB and its consequences on liver injury compared with CHC and NAFLD…

    FibroTest SteatoTest HBV HCV +1

  50. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Match 89

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight…

    Metabolic

  51. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.

    Bril F et al. · Diabetes Care · 2020 Match 89

    …nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However…

    FibroTest NashTest-2 Metabolic

  52. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 89

    liver injury are less well validated in non-alcoholic fatty liver disease…

    ActiTest FibroTest SteatoTest Metabolic

  53. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

    Jacqueminet S et al. · Clin Gastroenterol Hepatol · 2008 Match 88

    ### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver

    FibroTest SteatoTest Metabolic

  54. Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis.

    Brener S · Ont Health Technol Assess Ser · 2015 Match 88

    …B virus, nonalcoholic fatty liver disease, alcoholic liver disease, or cholestatic diseases…

    Elasto-FibroTest FibroTest Alcohol HBV +3

  55. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 88

    …Children present severe fatty liver disease with early cirrhosis. Before enzyme replacement…

    FibroTest Metabolic

  56. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 88

    …silybum marianum on non alcoholic fatty liver disease (NAFLD). ### Methods In 72…

    SteatoTest Metabolic

  57. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.

    Bauer B et al. · JAMA Dermatol · 2017 Match 87

    …All patients in the cohort except 1 were managed without a liver

    FibroTest NashTest

  58. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 87

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  59. The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.

    Gruszewska E et al. · Clin Lab · 2015 Match 87

    ### Background The aim of this study was to evaluate the prevalence of…

    AshTest NashTest Alcohol

  60. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 87

    …GH or for differentiation of this situation from nonalcoholic fatty liver disease.

    FibroTest Metabolic

  61. Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Review

    Kovalic AJ et al. · Eur J Gastroenterol Hepatol · 2023 Match 86

    ### Background Fibrosis impacts long-term outcomes among patients with nonalcoholic fatty liver

    FibroTest Metabolic

  62. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

    Bril F et al. · J Investig Med · 2019 Match 86

    …those patients with non-alcoholic fatty liver disease (NAFLD) by ^1^H…

    ActiTest FibroTest NashTest SteatoTest +1

  63. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 86

    …B, alcoholic liver disease, and non-alcoholic fatty liver disease, and were…

    SteatoTest Alcohol HBV HCV +1

  64. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.

    Mahamid M et al. · Clin Pharmacol · 2011 Match 86

    ### Background Elevation of liver enzymes in rheumatoid arthritis patients treated with tocilizumab…

    FibroTest Other

  65. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 86

    …Although ultrasound is still accepted as an initial screen for fatty liver

    FibroTest Alcohol

  66. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 85

    …the prediction of non-alcoholic liver disease by non-invasive blood tests…

    FibroTest NashTest-2 SteatoTest Metabolic

  67. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 85

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  68. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 85

    …for the diagnostic of metabolic liver disease in patients with type-2…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  69. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 85

    Liver fibrosis, as the last stage of numerous chronic liver diseases, is…

    ActiTest FibroTest Alcohol HBV +2

  70. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 84

    …of fibrosis in non-alcoholic fatty liver disease (NAFLD) with results similar…

    FibroTest Alcohol HBV HCV +1

  71. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 84

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  72. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 84

    ### Background The diagnosis of alcoholic liver diseases is based on the history…

    ActiTest AshTest FibroTest NashTest +2

  73. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 84

    …and metabolic-dysfunction-associated steatotic liver disease (MASLD); however, the underlying mechanisms…

    FibroTest Metabolic

  74. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 83

    …were both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66%, NAFLD…

    FibroTest Alcohol HBV HCV +3

  75. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.

    Golabi P et al. · Expert Rev Gastroenterol Hepatol · 2016 Match 83

    Nonalcoholic steatohepatitis (NASH) can lead to complications such as liver failure, cirrhosis…

    FibroTest Metabolic

  76. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 83

    …evaluated for the assessment of liver fibrosis predominantly in patients with viral…

    FibroTest SteatoTest Other

  77. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 83

    …2-diabetes (T2D), obesity, and liver fibrosis (resmetirom) announce the widespread use…

    FibroTest-T2D Metabolic

  78. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 83

    …UK Biobank with apparently healthy liver participants (middle-aged, n=138,125…

    FibroTest

  79. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.

    Canivet CM et al. · Hepatology · 2023 Match 82

    …of this algorithm in nonalcoholic fatty liver disease (NAFLD). ### Approach And Results…

    FibroTest Metabolic

  80. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.

    Codjia T et al. · Obes Surg · 2021 Match 82

    …therapeutic options for non-alcoholic fatty liver disease (NAFLD), affecting 90% of…

    FibroTest NashTest SteatoTest Metabolic

  81. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016 Match 82

    …the liver-related prognosis in patients with non-alcoholic fatty liver disease…

    FibroTest Metabolic

  82. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 82

    FibroTest Alcohol HBV HCV +3

  83. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 81

    …The rate of adoption of non-invasive diagnostic tests for liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  84. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 81

    …Routine assessment of liver fibrosis was requested by the surveyed physicians mostly…

    FibroTest Alcohol HBV HCV +3

  85. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 81

    …alcoholic (NAFLD) and alcoholic (ALD) fatty liver diseases. This review summarizes the…

    FibroTest Alcohol HBV HCV +3

  86. Biomarkers of liver fibrosis.

    Poynard T et al. · Adv Clin Chem · 2008 Match 81

    …C virus (HCV), hepatitis B virus (HBV), hepatitis nonalcoholic fatty liver disease…

    ActiTest FibroTest SteatoTest Alcohol +5

  87. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 80

    Alcohol is one of the main factors of liver damage. The evaluation…

    FibroTest Alcohol

  88. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 80

    Fatty liver develops in more than 90% of heavy drinkers, however only…

    FibroTest Alcohol

  89. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 80

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  90. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 80

    …Investigations included assessment of abdominal ultrasonography, liver biopsy, calculation of body mass…

    HCV

  91. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 79

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  92. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 79

    …alcoholic fatty liver disease (NAFLD), and 218 with alcoholic fatty liver disease…

    FibroTest Alcohol HBV HCV +1

  93. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 79

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  94. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 79

    ### Introduction Identifying liver fibrosis is important to evaluate the severity of liver

    FibroTest

  95. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 79

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  96. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 78

    …chronic liver diseases such as viral hepatitis and nonalcoholic fatty liver disease…

    FibroTest Alcohol

  97. Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 78

    FibroTest HBV

  98. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 78

    …The best marker of liver fibrosis in alcoholic patients seems to be…

    FibroTest Alcohol

  99. Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.

    Istaces N et al. · Clin Biochem · 2015 Match 78

    …and F3 liver fibrosis stages in non-alcoholic fatty liver disease with…

    FibroTest HBV HCV

  100. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.

    Rinella ME et al. · J Hepatol · 2022 Match 77

    ### Background & Aims Non-alcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver

    FibroTest Metabolic

  101. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

    Poynard T et al. · Expert Rev Mol Diagn · 2005 Match 77

    Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…

    ActiTest FibroTest Alcohol HBV +2

  102. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 77

    FibroTest Alcohol

  103. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 77

    …Progressive liver injury is a concern in HIV-infected children exposed to…

    FibroTest HIV

  104. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 76

    …However, liver biopsy is not replaceable, especially to diagnose ≥F2 and in…

    FibroTest HBV HCV HIV +1

  105. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 76

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  106. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 76

    …competitor as a biomarker of liver fibrosis in comparison with the standard…

    ActiTest FibroTest SteatoTest Alcohol +3

  107. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2012 Match 76

    …patients with chronic liver disease or normal liver tissue that surrounded tumors…

    FibroTest Alcohol HBV HCV +3

  108. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication

    Halfon P et al. · Gastroenterol Clin Biol · 2008 Match 75

    …CHB), alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD…

    FibroTest Alcohol HBV HCV +2

  109. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023 Match 75

    FibroTest Metabolic

  110. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 75

    …Steatosis was demonstrated in all 5 patients who received liver biopsies during…

    FibroTest Other

  111. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 75

    …transferrin (CDT%), is confounded by liver disease severity. The aim was to…

    FibroTest SteatoTest Alcohol

  112. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 75

    …Histologic staging of liver fibrosis served as the reference standard. ### Results Liver

    FibroTest Alcohol HBV HCV +2

  113. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 74

    …Non-invasive methods for the diagnosis of liver fibrosis, such as transient…

    FibroTest Other

  114. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Match 74

    …Histological features were assessed invasively by liver biopsy and noninvasively using FibroTest…

    ActiTest FibroTest SteatoTest HCV

  115. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.

    Poynard T et al. · BMC Gastroenterol · 2011 Match 74

    ### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…

    ActiTest FibroTest Alcohol HBV +4

  116. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 74

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  117. Meta-analyses of FibroTest diagnostic value in chronic liver disease.

    Poynard T et al. · BMC Gastroenterol · 2007 Match 73

    …chronic hepatitis B (CHB), alcoholic liver disease (ALD) and non-alcoholic fatty

    FibroTest Alcohol HBV HCV +1

  118. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 73

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  119. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 73

    …Further studies are needed to guide strategies for surveillance of liver disease…

    FibroTest

  120. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 73

    …of non-invasive biomarkers in liver fibrosis. A scoring system has been…

    ActiTest FibroTest SteatoTest Alcohol +5

  121. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 72

    ActiTest FibroTest Alcohol HBV +3

  122. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 72

    ### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  123. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 72

    …AshTest is an appropriate non-invasive alternative to transjugular liver biopsy.

    AshTest Alcohol

  124. [The prevalence of liver and gallbladder pathologies in overweight and obese patients].

    Popova IR et al. · Klin Med (Mosk) · 2012 Match 72

    …Nonalcoholic fatty liver disease was diagnosed using hepatic elastography and senrum markers…

    ActiTest FibroTest NashTest SteatoTest +1

  125. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.

    Ducancelle A et al. · J Clin Gastroenterol · 2017 Match 72

    liver fibrosis in chronic hepatitis C (CHC) and non-alcoholic fatty liver

    FibroTest Alcohol HBV HCV +2

  126. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012 Match 71

    ### Background & Aims Most liver transplant centres have discontinued the practice of protocol…

    ActiTest FibroTest Alcohol HBV +4

  127. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 71

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

  128. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 71

    …in the prediction of primary liver cancer in patients without cirrhosis. ### Aim…

    LCR1 LCR2 Alcohol HBV +4

  129. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 71

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver

    FibroTest HCV

  130. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 70

    …in order to avoid the liver biopsy currently used for selection of…

    FibroTest HCV

  131. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

    El-Shabrawi MH et al. · Eur J Gastroenterol Hepatol · 2010 Match 70

    Liver biopsy, because of its limitations and risks, might be considered an…

    ActiTest FibroTest HCV

  132. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 70

    …SVR benefits are well-recognized with reductions in rates of liver complications…

    FibroTest HCV

  133. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 70

    FibroTest Other

  134. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 69

    …The optimal cut-off values of liver stiffness (LS) for predicting METAVIR…

    FibroTest Alcohol

  135. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.

    Vermehren J et al. · Liver Int · 2012 Match 69

    …54 ± 11 years) with chronic liver disease and established cirrhosis were included…

    FibroTest Alcohol HBV HCV +3

  136. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

    Leroy V et al. · J Hepatol · 2007 Match 69

    ### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…

    FibroTest HCV

  137. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 69

    ActiTest FibroTest HBV

  138. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

    Kim BK et al. · PLoS One · 2012 Match 68

    ### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…

    FibroTest HBV

  139. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 68

    FibroTest Alcohol HBV HCV +1

  140. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 68

    ### Background And Aims Blood tests and liver stiffness evaluation (LSE) by ultrasonographic…

    FibroTest Alcohol HBV HCV +2

  141. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008 Match 68

    FibroTest Alcohol HBV HCV +1

  142. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 68

    ActiTest AshTest FibroTest NashTest +7

  143. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 67

    …risk for intestinal failure-associated liver disease (IFALD). The aim of the…

    FibroTest SteatoTest Other

  144. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 67

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  145. Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

    Gressner OA et al. · Clin Chim Acta · 2009 Match 67

    …serum-based assessment of liver fibrosis is still an important diagnostic challenge…

    ActiTest FibroTest HCV

  146. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 67

    …To evaluate the association between anthropometric measurements and advanced liver disease in…

    ActiTest FibroTest HCV

  147. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 66

    FibroTest Other

  148. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 66

    …The Enhanced Liver Fibrosis (ELF) test consists of an algorithm of three…

    FibroTest HBV HCV Other

  149. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 66

    ### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…

    FibroTest Alcohol

  150. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 66

    ActiTest FibroTest HCV

  151. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 65

    …followed for a risk of liver fibrosis risk in the USA (212…

    FibroTest COVID

  152. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011 Match 65

    FibroTest HCV

  153. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 65

    …The impact of treatment with ADV vs placebo was assessed on liver

    ActiTest FibroTest HBV

  154. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.

    Terrier B et al. · J Hepatol · 2011 Match 65

    …Serum levels of 25(OH)D3 were also significantly correlated with liver

    ActiTest FibroTest HCV HIV

  155. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.

    Sturm N et al. · Liver Int · 2013 Match 65

    ### Background Liver fibrosis, now assessed by liver biopsy or using non-invasive…

    FibroTest HBV HCV

  156. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 64

    …The use of AshTest may reduce the need for liver biopsy, and…

    AshTest Alcohol

  157. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 64

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  158. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication

    Nguyen-Khac E et al. · Aliment Pharmacol Ther · 2008 Match 64

    ### Background Systematic screening for liver fibrosis in heavy-drinking patients is a…

    FibroTest Alcohol

  159. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 64

    …of liver disease severity. ### Objective To compare the awareness of liver disease…

    ActiTest FibroTest Alcohol HBV +3

  160. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 63

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  161. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 63

    Liver disease in UCDs may be associated with hepatic inflammation, hepatic fibrosis…

    ActiTest FibroTest Other

  162. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 63

    ### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…

    FibroTest Alcohol

  163. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 63

    …infection or non-HCV-related liver diseases. ### Methods And Results The optimal…

    FibroTest Alcohol HBV HCV +2

  164. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

    Poynard T et al. · Clin Chem · 2004 Match 62

    ### Background The FibroTest and ActiTest are noninvasive biochemical markers of liver injury…

    ActiTest FibroTest HCV

  165. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.

    Dezanet LNC et al. · Liver Int · 2021 Match 62

    ### Background & Aims Data on liver fibrosis evolution and its involvement in liver

    FibroTest HBV HIV

  166. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011 Match 62

    ### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…

    FibroTest HCV

  167. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 62

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  168. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 61

    Chronic hepatitis B virus (HBV) infection is a major cause of liver

    FibroTest HBV

  169. American Association for the Study of the Liver

    Match 61

    FibroTest HCV

  170. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 61

    …these findings in women and in people with other chronic liver diseases.

    FibroTest HCV

  171. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 61

    The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…

    FibroTest HBV HCV HIV

  172. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 61

    Liver biopsy may be used in patients with suspected ALD to confirm…

    FibroTest Alcohol

  173. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 60

    …Although, liver biopsy is still considered as gold standard to identify liver

    FibroTest HCV

  174. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 60

    ### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver

    FibroTest HCV

  175. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 60

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  176. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.

    Shlomai A et al. · J Viral Hepat · 2013 Match 60

    Serum bile acids (SBAs) are commonly elevated in cholestatic liver diseases, but…

    FibroTest HCV

  177. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.

    Bonnard P et al. · J Viral Hepat · 2015 Match 59

    In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…

    FibroTest HCV

  178. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 59

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver

    FibroTest Other

  179. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.

    Mbaye PS et al. · PLoS One · 2011 Match 59

    …We sought to evaluate liver stiffness measurement by FibroScan® (LSM) and two…

    FibroTest HBV

  180. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

    Myers RP et al. · Dig Dis Sci · 2003 Match 59

    As an alternative to liver biopsy, an index of five biochemical markers…

    FibroTest HCV

  181. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 58

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  182. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

    Colletta C et al. · Hepatology · 2005 Match 58

    …We aimed to verify whether monitoring by liver biopsy might be replaced…

    FibroTest HCV

  183. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 58

    …For the prediction of survival without liver-related death, the areas under…

    FibroTest Alcohol HBV HCV +3

  184. Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest).

    Munteanu M et al. · Comp Hepatol · 2004 Match 58

    …These consisted of 29 healthy volunteers and 35 patients with chronic liver

    ActiTest FibroTest Alcohol HBV +3

  185. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 58

    ### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…

    FibroTest HCV HIV

  186. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 57

    …with chronic liver disease and either histological assessment of liver fibrosis (n…

    FibroTest Alcohol HBV HCV +2

  187. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.

    Corradi F et al. · Dig Liver Dis · 2009 Match 57

    ### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…

    FibroTest HCV

  188. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

    Crisan D et al. · Hepat Mon · 2012 Match 57

    …management of patients with chronic liver disease. Non-invasive tests (NITs) have…

    FibroTest HCV

  189. Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.

    Brühl J et al. · Eur J Gastroenterol Hepatol · 2011 Match 57

    …Results of noninvasive liver fibrosis markers were as follows: fibrotest,-1.65…

    FibroTest Other

  190. Reproducibility of blood tests of liver fibrosis in clinical practice.

    Calès P et al. · Clin Biochem · 2008 Match 56

    ### Objectives To evaluate the inter-laboratory reproducibility of blood test for liver

    FibroTest Alcohol HBV HCV +1

  191. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 56

    …a Model for End-Stage Liver Disease score ≥ 10 (24% [14-37…

    FibroTest HCV

  192. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 56

    …compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography…

    FibroTest Alcohol HBV HCV +3

  193. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 56

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest COVID

  194. Progression of liver fibrosis among injection drug users with chronic hepatitis C.

    Wilson LE et al. · Hepatology · 2006 Match 55

    …Baseline liver biopsies were obtained (1996-1998) on a random sample of…

    FibroTest

  195. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 55

    ### Background Liver stiffness and non-invasive tests predict overall survival in chronic…

    FibroTest HBV

  196. [Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].

    Piton A et al. · Ann Biol Clin (Paris) · 2005 Match 55

    ### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…

    ActiTest FibroTest

  197. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 55

    …Prevalence of significant liver-fibrosis assessed by TE, ARFI-right-liver-lobe…

    FibroTest Other

  198. Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.

    Wilson TG et al. · Int J Cardiol · 2018 Match 54

    ### Background Hepatic and renal dysfunction have been observed in survivors of the…

    FibroTest Other

  199. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 54

    …All patients had a liver biopsy. The Hepascore and FibroTest were calculated…

    FibroTest Other

  200. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 54

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  201. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 54

    FibroTest HBV

  202. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 54

    …better biomarkers of drug-induced-liver-injury (DILI). ### Aims We aimed to…

    ActiTest FibroTest Other

  203. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 53

    …including hepatic necroinflammatory activity, on liver stiffness measurement (LSM). This prospective study…

    FibroTest HCV

  204. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.

    Gangadharan B et al. · PLoS One · 2012 Match 53

    ### Background Liver biopsy is the reference standard for assessing liver fibrosis and…

    FibroTest HCV

  205. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 53

    …In this case, liver biopsy is still required to properly assess liver

    FibroTest HCV

  206. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 53

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  207. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 52

    Liver biopsy is the reference standard for assessment of liver fibrosis. However…

    FibroTest HBV

  208. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 52

    …enrolled 103 patients for whom liver biopsy, hepatic elastography results, and laboratory…

    ActiTest FibroTest AIH

  209. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 52

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  210. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 52

    ### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…

    FibroTest HCV HIV

  211. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 51

    ### Objectives Extent of liver fibrosis is one of the most important factors…

    FibroTest HBV

  212. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 51

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  213. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 51

    ActiTest FibroTest HBV

  214. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.